Pharvaris Netherlands B.v.
Clinical trials sponsored by Pharvaris Netherlands B.v., explained in plain language.
-
New pill could stop dangerous swelling attacks in hereditary angioedema patients
Disease control ENROLLING_BY_INVITATIONThis study tests an oral medication called deucrictibant for quickly treating sudden swelling attacks in people with hereditary angioedema (HAE), including life-threatening throat swelling. About 150 adults who have completed earlier studies or are new to the drug will take the p…
Phase: PHASE2, PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New daily pill aims to stop HAE attacks in their tracks
Disease control OngoingThis study tests a once-daily pill called deucrictibant to prevent sudden swelling attacks in people aged 12 and older with hereditary angioedema (HAE). Participants will take either the study drug or a placebo for 24 weeks to see if it reduces the number of attacks. The goal is …
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC